A clinical trial of MAO-B inhibitors conducted by the Parkinson Disease Research Group of the UK reported that selegiline therapy was associated with increased cardiovascular mortality,19 but this finding has not been replicated in the PD MED study1 or other clinical trials included in a meta-analysis.20 The gene discussed is MAOB; the disease is Parkinson disease.